Posterior Encephalopathy Syndrome (PRES) in Hepatitis C Virus (HCV)-Associated Seronegative Cryoglobulinemia and Active Hepatitis C: A Diagnostic and Therapeutic Challenge (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0713; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Current guidelines recommend combining DAAs with rituximab for severe HCV-associated cryoglobulinemic vasculitis; however, in this patient, given improvement with BP control alone, the absence of progressive or life-threatening organ involvement, and the elevated risk of infection with high-titer active HCV, immunosuppression was deferred in favour of outpatient DAA therapy. This case underscores the need for a decision-making framework when managing PRES in seronegative cryoglobulinemic vasculitis with concurrent active HCV."
Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Epilepsy • Glomerulonephritis • Hepatitis C • Hepatology • Hypertension • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Vasculitis
|
|
Syeda H. Imtiaz; Osama Kunwer Naveed
|